Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes

摘要

Aims: To analyse the effect of baseline glycated haemoglobin (HbA1c) on the reductionin HbA1c with empagliflozin compared with sitagliptin or glimepiride in patientswith type 2 diabetes.Materials and methods: Using regression analyses of individual patient data fromtwo Phase III studies, we compared the change in HbA1c according to a unit changein baseline HbA1c (the slope) with empagliflozin 10 mg or 25 mg vs sitagliptin (monotherapy)after 24 weeks, and with empagliflozin 25 mg vs glimepiride (as add-ontometformin) after 52 weeks.Results: Steeper slopes of HbA1c decline were observed with empagliflozin 10 or25 mg vs sitagliptin monotherapy at week 24. Regression analysis showed slopes of.0.59 (95% CI .0.70, .0.47), .0.49 (95% CI .0.62, .0.37) and .0.29 (95% CI .0.42,.0.15) for empagliflozin 10 mg, empagliflozin 25 mg and sitagliptin, respectively(P < .001 and P < .05 for empagliflozin 10 mg and empagliflozin 25 mg, respectively, vssitagliptin). Similarly, a steeper slope of HbA1c decline was observed with empagliflozin25 mg vs glimepiride as add-onto metformin at week 52. Regression analysis showedslopes of . 0.52 (95% CI .0.59, .0.44) and .0.32 (95% CI .0.39, .0.25) for empagliflozin25 mg and glimepiride, respectively (P < .001 for empagliflozin 25 mg vs glimepiride).Conclusions: Incremental reductions in HbA1c with increasing baseline HbA1c aregreater with empagliflozin compared with sitagliptin or glimepiride in patients withtype 2 diabetes.